Intervacc

Intervacc is a Swedish animal-health company that develops and commercializes vaccines for infectious diseases in horses and livestock. Its business is built around a proprietary recombinant fusion-protein technology platform and includes vaccine development, veterinary medicine distribution, and diagnostic services through its group companies.

— Intervacc
%
Vaccines for horses60% Vaccines and related development for equine infectious diseases, centered on Strangvac.
Veterinary medicines distribution20% Distribution of veterinary medicines in the Scandinavian market through Nordvacc Läkemedel AB.
Veterinary diagnostics10% Laboratory diagnostic services in veterinary bacteriology through Mybac-Vettech AB.
Pipeline vaccines and R&D10% Development-stage vaccine projects for pig and other animal infections.

Intervacc sells to veterinarians, horse owners, equine practices, and animal-health distributors that serve the horse...

  • Equine veterinarians and clinicsprimary

    Buy or recommend Strangvac to prevent equine strangles in horse populations.

  • Horse owners and stable operatorsprimary

    Use vaccines to reduce outbreak risk and protect horse herds.

  • Veterinary medicine distributorssecondary

    Purchase and distribute veterinary medicines in Scandinavian markets.

  • Pig producers and veterinariansemerging

    Potential future buyers of Streptococcus suis vaccines to reduce disease losses.

  • Diagnostic laboratory customerssecondary

    Use bacteriology testing services for veterinary diagnosis and monitoring.

Intervacc is headquartered in Sweden and operates through a Scandinavian distribution and diagnostics footprint...

  • •Headquartered in Sweden with group operations in Scandinavia
  • •Strangvac is sold in several important European markets
  • •Europe is the core commercial geography for the lead vaccine
  • •The U.S. is a regulatory expansion target for Strangvac
  • •Pipeline projects address global horse and pig markets

Intervacc’s strategy is to build a commercial animal-health franchise around Strangvac while advancing follow-on...

01
Commercialize Strangvac in core horse marketsshort-term

The lead product anchors current revenue potential and brand recognition.

02
Obtain U.S. market accessmedium-term

The U.S. horse market expands the addressable customer base for Strangvac.

03
Advance the Streptococcus suis pipelinemedium-term

A second successful vaccine would diversify the product base and reduce dependence on one asset.

04
Scale the recombinant fusion-protein platformlong-term

The same platform can support multiple animal-health indications and improve pipeline efficiency.

Intervacc is exposed to commercialization risk because a large share of its value depends on Strangvac’s market...

high

Dependence on Strangvac commercialization

Only one vaccine project is currently launched and able to generate revenue, so underperformance would affect valuation and forecasts.

Scope
Lead product concentration
Materiality
high
high

Financing risk

Drug R&D is capital intensive and the company may need external funding to support operations and development.

Scope
Ongoing R&D and commercialization funding
Materiality
high
high

Manufacturing disruption

The company relies on contracted external manufacturers for vaccine components, filling, and packaging.

Scope
Supply chain and production continuity
Materiality
high
medium

Regulatory approval risk

U.S. commercialization requires USDA-related approval, which can be lengthy and uncertain.

Scope
Market expansion into the United States
Materiality
medium
medium

Key employee dependence

Loss of senior executives or technical staff could slow development and commercial execution.

Scope
R&D and commercialization leadership
Materiality
medium
K3 accounting framework
Reported earnings and balance sheet values
Impairment and recoverability judgments
Intangible assets and forecast assumptions
R&D expense timing
Operating result and comparability
External manufacturing and launch costs
Quarterly expense volatility
Grant accounting
Net R&D cost presentation

Immunovant, Inc.

IMVT · Biological Products, (No Diagnostic Substances)

NOVAVAX INC

NVAX · Biological Products, (No Diagnostic Substances)

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

INTERPACE BIOSCIENCES, INC.

IDXG · Surgical & Medical Instruments & Apparatus

DYNAVAX TECHNOLOGIES CORP

Pharmaceutical Preparations

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

: 11/08/2026